Key Insights

Highlights

Treatment Research

3 treatments under study, led by Immediate Azathioprine 1st Attack

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05545384Phase 3Recruiting

Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial

Showing all 1 trials

Research Network

Common Treatments

  • Immediate Azathioprine 1st Attack1
  • Immediate Rituximab 1st Attack1
  • Standard Of Care1

Active Sponsors

  • Assistance Publique - Hôpitaux de Paris1
  • Assistance Publique Hopitaux De Paris1
  • Institut National de la Santé Et de la Recherche Médicale, France1

Related Conditions

  • Myelin Oligodendrocyte Glycoprotein Antibodyassociated Disease1
  • Acute Demyelinating Syndrome1

Activity Timeline